CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...